Application of in-house monoclonal antibody resources to a fully retargeted oncolytic herpes simplex virus platform

我们已经报道了一个完全重靶向的单纯疱疹病毒（HSV）平台，该平台包含单链抗体，可以通过肿瘤相关抗原介导病毒的进入。为了进一步开发该系统，我们成功地利用了我们自己收集的针对人类癌症的单克隆抗体。我们的研究结果表明，我们的系统对不同靶向配体的适应性，导致新一代广泛适用和有效的溶瘤性HSV载体。

We have reported a fully retargeted herpes simplex virus (HSV) platform that incorporates single-chain antibodies to mediate virus entry exclusively via tumor-associated antigens. For further development of this system, we successfully took advantage of our own collection of monoclonal antibodies directed against human cancers. Our results indicate the adaptability of our system to different targeting ligands, leading to a new generation of broadly applicable and effective oncolytic HSV vectors.